Vividion Secures $82 Million to Advance Its Lead Programs into the Clinic
Vividion Therapeutics snagged $82 million in an oversubscribed Series B funding round to bolster its cash holdings that will be used to...
top of page
A L T I T U D E
Life Science Ventures
Companies in the News
- Apr 22, 2019
Gritstone Oncology Announces Clinical Acceleration of “Off-The-Shelf” Personalized Neoantigen Immuno
EMERYVILLE, Calif., April 22, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), an immuno-oncology company developing...
- Apr 2, 2019
BlackThorn Therapeutics Announces Positive Phase 1 Results for Its Selective KOR Antagonist, BTRX-33
Phase 1 results and new translational data supporting the development of BTRX-335140 for neurobehavioral disorders presented at the Kappa...
bottom of page